Flow cytometric approach to the diagnosis and classification of mature B-cell lymphoid neoplasm 가천의대길병원진단검사의학과 안정열
|
|
|
- Barbra Bond
- 7 years ago
- Views:
Transcription
1 Flow cytometric approach to the diagnosis and classification of mature B-cell lymphoid neoplasm 가천의대길병원진단검사의학과 안정열
2 Mature B-cell neoplasm 1. Mature B-cell : SIg(+) & lack of Ags of immaturity (TdT, CD34) or weak CD45 2. Diagnosis of mature B-cell lymphoma by FCM 1) identification of phenotypically abnormal cells 2) recognition of phenotypes characteristic of separate disease entities 3) provide prognostic information (CD38 in CLL) 4) evaluation of MRD (minimal residual disease) 5) identify targets for potential Ab-direct Tx
3 Identification of abnormal mature B-lymphoid cells I. Immunoglobulin light chain class restriction II. Aberrant antigen expression III. Significance of small populations of phenotypically abnormal B cells Flow cytometric classification of mature B-cell neoplasms
4 Identification of abnormal mature B-lymphoid cells I. Immunoglobulin light chain restriction 1. Neoplasm of mature B cells usually express only one class of Ig light chain (i.e., kappa or lambda), used as a surrogate marker of clonality 2. 고려할점 : (1) Ig light chain restriction = monoclonality? (2) Interpretation of staining for κ/λ
5 lambda kappa kappa lambda CD45 CD19 CD19
6 (1) Ig light chain restriction monoclonality 1) the presence of a clonal B-cell process by FCM : κ/λ ratios of more than 3.0 or less than 0.5 2) Rare monoclonal λ light chain restriction in reactive B-cell - monoclonal proliferations in tonsillar specimen in childhood. - multicentric Castleman disease - germinal center B cells in Hashimoto s thyroiditis => Ig light chain restriction is not synonymous with monoclonality or neoplasia 3) Light chain restricted populations that are truly monoclonal are not neoplastic : florid follicular hyperplasia in patients with HIV
7 (2) Interpretation of staining for κ/λ 1) Nonspecific (cytophilic ) binding - Fc receptor - adherence of Ab to sticky cells (damaged or dying cells) 2) Lack of staining for surface Ig - true weak or negative : lymphoblast (ALL), plasma cell (PCN), thymic B cell (mediastinal B-cell lymphoma), CLL -false negative ; soluble Ab interfere with the binding of detection Ab ( 해결 : initial wash step ) ; the epitope recognized has been deleted or altered (more frequently with MoAb than polyab)
8 CD45 CD19 lambda CD19 lambda kappa kappa
9 CD16 CD45 CD16 CD3 CD56 CD56
10
11 kappa lambda
12 poly lambda poly kappa
13 II. Aberrant antigen expression (1) the presence of Ags not normally expressed by B cells ( CD5 in CLL, CD13 or CD33 in LPL) (2) not typically present in a subset of B cells ( CD10+/bcl 2+ in follicular lymphoma) (3) alteration in intensity of staining for B-lineage associated Ags (dim CD19 and brighter CD10 in FL)
14 III. Significance of small populations of phenotypically abnormal B cells (1) Less than 5% of the total cells analyzed (2) In the staging of pts with previously characterized lymphoma => if the phenotype matches, can be used to determine the presence of involvement (3) do not have a previous diagnosis of lymphoid malignancy => significance is less clear ex) insignificant CLL-like populations in PB and BM from older patients =>it should not be used to establish a new diagnosis.
15 Flow cytometric classification of mature B-cell neoplasms (1) Useful to consider 4 broad groups as determined by their expression of CD5 and CD10 (2) CD5+ CD10- CD5- CD10+ CD5- CD10- CD5+ CD10+
16
17 Ab cocktails used in B-cell lymphoma (1) CD5/CD38/CD45/CD19 (2) Lambda/Kappa/CD45/CD19 (3) FMC7/CD23/CD45/CD22 (4) CD20/CD10/CD45/CD19
18 CD5/CD38/CD45/CD19 1) Aid in enumerating T and B cells 2) Assess CD5 expression on B cells 3) Assess CD38 on CD19+ cells to distinguish between activated mature B cells, hematogones, and plasma cells 4) Assess CD38 expression on CLL
19 CD5 CD5
20 CD19 CD5 CD38 CD38 CD45 CD19 CD5
21 CD45 CD19 CD5 CD19 CD5 CD38 CD38
22 Lambda/Kappa/CD45/CD19 1) Aid in enumerating B cells 2) Assess light chain reactivity on B cells ( monotypic or polytypic) 3) CD19 gate : aids in - characterizing light chain pattern - evaluation for surface Ig negative cells - small abnormal populations
23 CD19 CD19 Anti-kappa Anti-kappa Anti-lambda Anti-lambda
24 lambda kappa kappa lambda CD45 CD19 CD19
25 CD19 lambda kappa CD19
26 FMC7/CD23/CD45/CD22 1) Aid in characterizing mature CD5+ small B cell neoplasm 2) Typical CLL: CD23+FMC7-3) Typical Mantle cell lymphoma : CD23-FMC7+ 4) Assess for lymph node pattern: bimodal CD23/FMC7 - germinal center B cells : brighter FMC7 - mantle zone B cells : brighter CD23
27 CD5 CD5
28 CLL CD23 CD45 CD22 FMC7 CD22 FMC7 CD23
29 MCL CD23 FMC7 CD45 CD23 CD22 CD22 FMC7
30
31 CD20/CD10/CD45/CD19 1) Evaluation CD10 expression on B cells 2) Confirm normal circulating B cell phenotype (CD19+CD20+CD10-) 4) Confirm hematogones (CD19+CD20variableCD10+) 5) Assess CD19 expression on B cells (ex; aberrant dim is common in FL) 6) Assess for germinal center pattern ( minority of GC B cells with dim CD10+and slightly brighter CD20) 7) CD19+CD10+CD20-: D/Dx of negative for CD20 in Tx with rituximab anti-cd20
32
33
34
35
36 Chronic lymphocytic leukemia (CLL)
37 CD5 CD38 CD38 CD5 CD45 CD19 CD19
38 CD45 lambda CD19 lambda kappa kappa CD19
39 CD45 CD22 FMC7 CD22 FMC7 CD23 CD23
40 CD20 CD10 CD10 CD20 CD45 CD19 CD19
41 Mantle cell lymphoma
42 CD5 CD45 CD38 CD38 CD19 CD19 CD5
43 lambda kappa kappa lambda CD45 CD19 CD19
44 CD45 FMC7 CD23 CD23 CD22 CD22 FMC7
45 CD20 CD10 CD10 CD45 CD19 CD20 CD19
46
47
48 Follicular lymphoma
49 CD45 CD19 CD5 CD19 CD5 CD38 CD38
50 Anti-lambda CD19 Anti-lambda Anti-kappa Anti-kappa CD45 CD19
51 CD45 CD19 CD20 CD19 CD20 CD10 CD10
52 CD23 CD23 CD45 FMC7 CD22 CD22 FMC7
53 or CD45 FMC7 CD23 CD23 CD22 CD22 FMC7
54 Diffuse Large B-cell lymphoma (DLBCL)
55 CD5 CD38 CD38 CD5 CD45 CD19 CD19
56 Anti-lambda Anti-kappa Anti-kappa CD45 CD19 CD19 Anti-lambda
57 CD20 CD10 CD10 CD20 CD45 CD19 CD19
58 FMC7 CD45 CD22 CD22 FMC7 CD23 CD23
59
60
61 Hairy cell leukemia
62 CD45 CD5 CD19 CD19 CD5 CD38 CD38
63 CD45 CD19 Anti-lambda CD19 Anti-lambda Anti-kappa Anti-kappa
64 CD10 CD20 CD45 CD19 CD19 CD20 CD10
65 CD11c CD45 CD103 CD11c CD19 CD19 CD103
66 CD45 CD19 CD103 CD19 CD103 CD25 CD25
67
68 Reference 1. Wood BL et al Bethesda International Consensus recommendations on the flow cytometric immunophenotypic analysis of hematolymphoid neoplasia by flow cytometry : optimal reagents and reporting for the flow cytometric diagnosis of hematopoietic neoplasia. Cytometry B Clin Cytom 2007;72B:S14-S Fiona E Craig and Kenneth A Foon. Flow cytometric immunophenotyping for hematologic neoplasm. Blood 2008;111: Chen W et al. Characterization of incidentally identified minute clonal B- lymphocyte populations in peripheral blood and bone marrow. Am J Clin Pathol 2004;122: Andy C Rawstron et al. Monoclonal B lymphocytes with the characteristics of indolent chronic lymphocytic leukemia are present in 3.5% of adults with normal blood counts. Blood 2002;100: Chizuka A et al. The diagnostic value of kappa/lambda ratios determined by flow cytometric analysis of biopsy specimens in B-cell lymphoma. Clin Lab Haem. 2002;24: Sharpe RW et al. Hairy cell leukemia:diagnostic pathology. Hematol Oncol Clin North Am 2006;20: Henry I Chen et al. Restricted κ/λ light chain ratio by flow cytometry in germinal center B cells in Hashimoto thyroiditis. Am J Clin Pathol 2006;125: Camellia Eshoa et al. Decreased CD10 expression in grade III and in interfollicular infiltrates of follicular lymphomas. Am J Clin Pathol 2001;115: Zach Liu et al. CD5- mantle cell lymphoma. Am J Clin Pathol 2002;118: Henry Y Dong et al. B-cell lymphomas with coexpression of CD5 and CD10. Am J Clin Pathol 2003;119:
Flow Cytometric Evaluation of B-cell Lymphoid Neoplasms
Clin Lab Med 27 (2007) 487 512 Flow Cytometric Evaluation of B-cell Lymphoid Neoplasms Fiona E. Craig, MD Division of Hematopathology, Department of Pathology, University of Pittsburgh School of Medicine,
Flow Cytometric Diagnosis of Low Grade B-cell Leukemia/Lymphoma
Flow Cytometric Diagnosis of Low Grade B-cell Leukemia/Lymphoma Maryalice Stetler-Stevenson, M.D., Ph.D. Flow Cytometry Unit, Laboratory of Pathology, DCS, NCI,NIH DEPARTMENT OF HEALTH & HUMAN SERVICES
LYMPHOMA. BACHIR ALOBEID, M.D. HEMATOPATHOLOGY DIVISION PATHOLOGY DEPARTMENT Columbia University/ College of Physicians & Surgeons
LYMPHOMA BACHIR ALOBEID, M.D. HEMATOPATHOLOGY DIVISION PATHOLOGY DEPARTMENT Columbia University/ College of Physicians & Surgeons Normal development of lymphocytes Lymphocyte proliferation and differentiation:
Flow Cytometry for Everyone Else Susan McQuiston, J.D., MLS(ASCP), C.Cy.
Flow Cytometry for Everyone Else Susan McQuiston, J.D., MLS(ASCP), C.Cy. At the end of this session, the participant will be able to: 1. Describe the components of a flow cytometer 2. Describe the gating
B-cell Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
2008 WHO Classification of Lymphoid Neoplasms: Small B-Cell Neoplasms Chronic lymphocytic leukemia/small lymphocytic lymphoma B-cell prolymphocytic leukemia Splenic marginal zone B-cell lymphoma Hairy
Interesting Case Review. Renuka Agrawal, MD Dept. of Pathology City of Hope National Medical Center Duarte, CA
Interesting Case Review Renuka Agrawal, MD Dept. of Pathology City of Hope National Medical Center Duarte, CA History 63 y/o male with h/o CLL for 10 years Presents with worsening renal function and hypercalcemia
Malignant Lymphomas and Plasma Cell Myeloma
Malignant Lymphomas and Plasma Cell Myeloma Dr. Bruce F. Burns Dept. of Pathology and Lab Medicine Overview definitions - lymphoma lymphoproliferative disorder plasma cell myeloma pathogenesis - translocations
Leukemias and Lymphomas: A primer
Leukemias and Lymphomas: A primer Normal blood contains circulating white blood cells, red blood cells and platelets 700 red cells (oxygen) 1 white cell Neutrophils (60%) bacterial infection Lymphocytes
Pathology No: SHS-CASE No. Date of Procedure: Client Name Address
TEL #: (650) 725-5604 FAX #: (650) 725-7409 Med. Rec. No.: Date of Procedure: Sex: A ge: Date Received: Date of Birth: Account No.: Physician(s): Client Name Address SPECIMEN SUBMITTED: LEFT PIC BONE MARROW,
Immunohistochemical classification of malignant lymphomas
Immunohistochemical classification of malignant lymphomas Prof. Mogens Vyberg NordiQC Institute of Pathology Aalborg, Denmark Thanks to Jan Klos Important issues Distinction from non-hematopoietic neoplasms
About B Cell Lymphomas Groupmeeting Klipp/Spang, December 09 2002 Dennis Kostka Max-Planck-Institute for Molecular Genetics Computational Molecular Biology Berlin 1 Overview Short History of Lymphoma Classification
Mature Lymphoproliferative disorders (2): Mature B-cell Neoplasms. Dr. Douaa Mohammed Sayed
Mature Lymphoproliferative disorders (2): Mature B-cell Neoplasms Dr. Douaa Mohammed Sayed Small lymphocytic lymphoma/b-cell chronic lymphocytic leukemia BMB: nodular, interstitial, diffuse or a combination
Utility of flow cytometric κ and λ light chain analysis of peripheral blood
JBUON 2015; 20(5): 1322-1326 ISSN: 1107-0625, online ISSN: 2241-6293 www.jbuon.com E-mail: editorial_office@jbuon.com ORIGINAL ARTICLE Utility of flow cytometric κ and λ light chain analysis of peripheral
Bone Marrow Evaluation for Lymphoma. Faizi Ali, MD Hematopathology Fellow William Beaumont Hospital
Bone Marrow Evaluation for Lymphoma Faizi Ali, MD Hematopathology Fellow William Beaumont Hospital Indications One of the most common indications for a bone marrow biopsy is to evaluate for malignant lymphoma.
Why discuss CLL? Common: 40% of US leukaemia. approx 100 pa in SJH / MWHB 3 inpatients in SJH at any time
Why discuss CLL? Common: 40% of US leukaemia approx 100 pa in SJH / MWHB 3 inpatients in SJH at any time Median age of dx is 65 (30s. Incurable, survival 2-202 20 years Require ongoing supportive care
Subtypes of AML follow branches of myeloid development, making the FAB classificaoon relaovely simple to understand.
1 2 3 4 The FAB assigns a cut off of 30% blasts to define AML and relies predominantly on morphology and cytochemical stains (MPO, Sudan Black, and NSE which will be discussed later). Subtypes of AML follow
DELPHI 27 V 2016 CYTOMETRY STRATEGIES IN THE DIAGNOSIS OF HEMATOLOGICAL DISEASES
DELPHI 27 V 2016 CYTOMETRY STRATEGIES IN THE DIAGNOSIS OF HEMATOLOGICAL DISEASES CLAUDIO ORTOLANI UNIVERSITY OF URBINO - ITALY SUN TZU (544 b.c. 496 b.c) SUN TZU (544 b.c. 496 b.c.) THE ART OF CYTOMETRY
Lymphoma Diagnosis and Classification
Lymphoma Diagnosis and Classification By Atef Shrit, MD, Pathology B- and T/NK-cell lymphomas are clonal neoplasms of immature and mature B-lymphocytes, T-lymphocytes or natural killer cells at various
Non-Hodgkin s Lymphoma
Non-Hodgkin s Lymphoma Luis Fayad, MD Assistant Professor Clinical Medical Director Lymphoma/Myeloma Department Non-Hodgkin s Lymphoma Non-Hodgkin s lymphomas (NHL) are a heterogeneous group of malignant
Lymphoplasmacytic Lymphoma. Hematology fellows conference 4/12/2013 Christina Fitzmaurice, MD, MPH
Lymphoplasmacytic Lymphoma versus IGM Multiple Myeloma Hematology fellows conference 4/12/2013 Christina Fitzmaurice, MD, MPH Hematology consult patient 48 yo woman presents to ER with nonspecific complaints:
Estimated New Cases of Leukemia, Lymphoma, Myeloma 2014
ABOUT BLOOD CANCERS Leukemia, Hodgkin lymphoma (HL), non-hodgkin lymphoma (NHL), myeloma, myelodysplastic syndromes (MDS) and myeloproliferative neoplasms (MPNs) are types of cancer that can affect the
chronic leukemia lymphoma myeloma differentiated 14 September 1999 Pre- Transformed Ig Surface Surface Secreted Myeloma Major malignant counterpart
Disease Usual phenotype acute leukemia precursor chronic leukemia lymphoma myeloma differentiated Pre- B-cell B-cell Transformed B-cell Plasma cell Ig Surface Surface Secreted Major malignant counterpart
A 32 year old woman comes to your clinic with neck masses for the last several weeks. Masses are discrete, non matted, firm and rubbery on
A 32 year old woman comes to your clinic with neck masses for the last several weeks. Masses are discrete, non matted, firm and rubbery on examination. She also has fever, weight loss, and sweats. What
An overview of CLL care and treatment. Dr Dean Smith Haematology Consultant City Hospital Nottingham
An overview of CLL care and treatment Dr Dean Smith Haematology Consultant City Hospital Nottingham What is CLL? CLL (Chronic Lymphocytic Leukaemia) is a type of cancer in which the bone marrow makes too
Monoclonal B-Cell Lymphocytosis
Monoclonal B-Cell Lymphocytosis Identification of parameters involved in the pathogenesis and in a higher risk of malignant transformation Belen Espinosa Degree project in biology, Master of science (2
Updating the 2008 WHO Classification of Small B cell lymphomas Elias Campo
Updating the 2008 WHO Classification of Small B cell lymphomas Elias Campo Hospital Clinic, University of Barcelona Barcelona, Spain Disclosure of Relevant Financial Relationships Dr. ELIAS CAMPO declares
MALIGNANT LYMPHOMAS. Dr. Olga Vujovic (Updated August 2010)
MALIGNANT LYMPHOMAS Dr. Olga Vujovic (Updated August 2010) Malignant lymphomas consist of Hodgkin and non-hodgkin lymphomas. The current management of these diseases involves a multi-disciplinary approach.
Too Many B Cells: Chronic Lymphocytic Leukemia and the Role of Flow Cytometry
Too Many B Cells: Chronic Lymphocytic Leukemia and the Role of Flow Cytometry by Debby R. Walser-Kuntz Biology Department Carleton College, Northfield, MN Taylor goes in to see her doctor, Dr. Chavez,
Adult Medical-Surgical Nursing H A E M A T O L O G Y M O D U L E : L E U K A E M I A 2
Adult Medical-Surgical Nursing H A E M A T O L O G Y M O D U L E : L E U K A E M I A 2 Leukaemia: Description A group of malignant disorders affecting: White blood cells (lymphocytes or leucocytes) Bone
for Leucocyte Immunophenotyping Leukaemia Diagnosis Interpretation All Participants Date Issued: 08-September-2014 Closing Date: 26-September-2014
for Leucocyte Immunophenotyping Leukaemia Interpretation All Participants Participant: 4xxxx Trial No: 141502 Date Issued: 08-September-2014 Closing Date: 26-September-2014 Trial Comments This was an electronic
Histopathologic results
Self evaluation 1 Clinical Case 55-year-old woman Bilateral enlargement of cervical, axillary and inguinal lymph nodes, largest diameter > 6 cm Hepatosplenomegaly. Enlargement of retroperitoneal, mesenteric
Chromosome 6 Abnormalities Associated with Prolymphocytic Acceleration in Chronic Lymphocytic Leukemia* f
ANNALS OF CLINICAL AND LABORATORY SCIENCE, Vol. 28, No. 1 Copyright 1998, Institute for Clinical Science, Inc. Chromosome 6 Abnormalities Associated with Prolymphocytic Acceleration in Chronic Lymphocytic
Chronic Lymphocytic Leukemia. Case Study. AAIM Triennial October 2012 Susan Sokoloski, M.D.
Chronic Lymphocytic Leukemia AAIM Triennial October 2012 Susan Sokoloski, M.D. Case Study 57 year old male, trial application for $1,000,000 Universal Life coverage Cover letter from sales agent indicates
WHICH SAMPLES SHOULD BE SUBMITTED WHEN LYMPHOID NEOPLASIA IS SUSPECTED?
WHICH SAMPLES SHOULD BE SUBMITTED WHEN LYMPHOID NEOPLASIA IS SUSPECTED? Which test should be submitted? The answer to this depends on the clinical signs, and the diagnostic question you are asking. If
Flow Cytometry A Guide for Data Analysis
Flow Cytometry A Guide for Data Analysis Last revisions 12 Aug 2013 Ron Lee, M.D. Introduction This guide is intended to provide a basic overview of clinical flow cytometry data analysis. General Principles
Immunophenotyping. Alberto Orfao, MD, PhD
Immunophenotyping Alberto Orfao, MD, PhD Introduction Immunophenotyping of biological samples refers to the use of immunological tools (e.g. monoclonal and/or polyclonal antibodies) for the specific detection
CD5-positive, Small B-Cell Lymphoproliferative Disorders: Aberrant Findings of CLL/SLL and MCL
North American Journal of Medicine and Science Oct 2010 Vol 3 No.4 181 CD5-positive, Small B-Cell Lymphoproliferative Disorders: Aberrant Findings of CLL/SLL and MCL Youjun Hu, MD, Marc Golightly, PhD
Outline of lecture. Disclosures. Current Issues in Practical Hematopathology: Diagnosis of Bone Marrow Lymphomas
Current Issues in Practical Hematopathology: Diagnosis of Bone Marrow Lymphomas Disclosures I have no disclosures relevant to the content of this lecture Robert P Hasserjian, MD Associate Professor Massachusetts
Hematopathology VII Acute Lymphoblastic Leukemia, Chronic Lymphocytic Leukemia, And Hairy Cell Leukemia
John L. Kennedy, M.D. UIC College of Medicine Associate Professor of Clinical Pathology M2 Pathology Course Lead Pathologist, VA Chicago Health Care System Lecture #43 Phone: (312) 569-6690 Thursday, November
B Cells and Antibodies
B Cells and Antibodies Andrew Lichtman, MD PhD Brigham and Women's Hospital Harvard Medical School Lecture outline Functions of antibodies B cell activation; the role of helper T cells in antibody production
Novel Use of the BD FACS TM SPA to Automate Custom Monoclonal Antibody Panel Preparations for Immunophenotyping
Cytometry Part B (Clinical Cytometry) 66B:40 45 (2005) TECHNICAL INNOVATION Novel Use of the BD FACS TM SPA to Automate Custom Monoclonal Antibody Panel Preparations for Immunophenotyping Abigail S. Kelliher,
Introduction. About 10,500 new cases of acute myelogenous leukemia are diagnosed each
Introduction 1.1 Introduction: About 10,500 new cases of acute myelogenous leukemia are diagnosed each year in the United States (Hope et al., 2003). Acute myelogenous leukemia has several names, including
Lauren Berger: Why is it so important for patients to get an accurate diagnosis of their blood cancer subtype?
Hello, I m Lauren Berger and I m the Senior Director of Patient Services Programs at The Leukemia & Lymphoma Society. I m pleased to welcome Dr. Rebecca Elstrom. Dr. Elstrom is an Assistant Professor in
Review Articles. Flow Cytometric Analysis of Lymphomas. Current Status and Usefulness. Zahid Kaleem, MD
Review Articles Flow Cytometric Analysis of Lymphomas Current Status and Usefulness Zahid Kaleem, MD Context. Immunophenotyping has become a routine practice in the diagnosis and classification of most
Four-Color Flow Cytometric Analysis of Myeloma Plasma Cells
Hematopathology / FLOW CYTOMETRIC ANALYSIS OF MYELOMA PLASMA CELLS Four-Color Flow Cytometric Analysis of Myeloma Plasma Cells Shoichi Kobayashi, MT, 1 Rie Hyo, MD, 2 Yukiko Amitani, MT, 1 Masatsugu Tanaka,
Pulling the Plug on Cancer Cell Communication. Stephen M. Ansell, MD, PhD Mayo Clinic
Pulling the Plug on Cancer Cell Communication Stephen M. Ansell, MD, PhD Mayo Clinic Why do Waldenstrom s cells need to communicate? Waldenstrom s cells need activating signals to stay alive. WM cells
Uses of Flow Cytometry
Uses of Flow Cytometry 1. Multicolour analysis... 2 2. Cell Cycle and Proliferation... 3 a. Analysis of Cellular DNA Content... 4 b. Cell Proliferation Assays... 5 3. Immunology... 6 4. Apoptosis... 7
Non neoplasticneoplastic condictions. Dipartimento di Scienze Biomorfologiche e Funzionali, Università di Napoli, Federico II Naples, Italy
European Federation of Cytology Societies 4tu Annual Tutorial in Cytopathology Trieste, June 6-10, 2011 Fine needle cytology of lymph nodes: Non neoplasticneoplastic condictions Pio Zeppa MD PhD Pio Zeppa
Waldenström Macroglobulinemia: The Burning Questions. IWMF Ed Forum May 18 2014 Morie Gertz MD, MACP
Waldenström Macroglobulinemia: The Burning Questions IWMF Ed Forum May 18 2014 Morie Gertz MD, MACP Are my kids going to get this? Familial seen in approximately 5 10% of all CLL patients and can be associated
Mantle Cell Lymphoma Understanding Your Treatment Options
New Developments in Mantle Cell Lymphoma John P. Leonard, M.D. Richard T. Silver Distinguished Professor of Hematology and Medical Oncology Associate Dean for Clinical Research Vice Chairman, Department
CLL: Disease Course, Treatment, Diagnosis, and Biomarkers
CLL: Disease Course, Treatment, Diagnosis, and Biomarkers Amy E. Hanlon Newell, Ph.D. Manager, Scientific Affairs Abbott Molecular Overview: Today s Take-away Understanding of: Cell phenotype and clinical
Re: Docket No. FDA-2014-D-1351; Draft Guidance for Industry and FDA Staff on Flow Cytometric Devices
Division of Dockets Management (HFA-305) Food and Drug Administration 5630 Fishers Lane, Room 1061 Rockville, MD 20852 Re: Docket ; Draft Guidance for Industry and FDA Staff on Flow Cytometric Devices
Standardization, Calibration and Quality Control
Standardization, Calibration and Quality Control Ian Storie Flow cytometry has become an essential tool in the research and clinical diagnostic laboratory. The range of available flow-based diagnostic
Hematology Morphology Critique
Survey Slide: History: 60-year-old female presenting with pneumonia Further Laboratory Data: Hgb : 90 g/l RBC : 2.92 10 12 /L Hct : 0.25 L/L MCV : 87 fl MCH : 30.8 pg MCHC : 355 g/l RDW : 17.7 % WBC :
specific B cells Humoral immunity lymphocytes antibodies B cells bone marrow Cell-mediated immunity: T cells antibodies proteins
Adaptive Immunity Chapter 17: Adaptive (specific) Immunity Bio 139 Dr. Amy Rogers Host defenses that are specific to a particular infectious agent Can be innate or genetic for humans as a group: most microbes
Corporate Medical Policy
Corporate Medical Policy Hematopoietic Stem-Cell Transplantation for CLL and SLL File Name: Origination: Last CAP Review: Next CAP Review: Last Review: hematopoietic_stem-cell_transplantation_for_cll_and_sll
SWOG ONCOLOGY RESEARCH PROFESSIONAL (ORP) MANUAL VOLUME I RESPONSE ASSESSMENT LEUKEMIA CHAPTER 11A REVISED: OCTOBER 2015
LEUKEMIA Response in Acute Myeloid Leukemia (AML) Response criteria in Acute Myeloid Leukemia for SWOG protocols is based on the review article Diagnosis and management of acute myeloid leukemia in adults:
Multiple Myeloma and Colorectal Cancer
Multiple Myeloma and Colorectal Cancer From Systems Immunology to Single Cells Leo Hansmann Mark M. Davis Lab Department of Microbiology&Immunology Stanford University Multiple Myeloma Monoclonal disease
Immunophenotyping in the differential diagnosis of histologically low grade B cell lymphomas
Current Diagnostic Pathology (2000) 6, 55 63 2000 Harcourt Publishers Ltd doi:10.1054/cdip.2000.0015, available online at http://www.idealibrary.com on REVIEW Immunophenotyping in the differential diagnosis
Activation and effector functions of HMI
Activation and effector functions of HMI Hathairat Thananchai, DPhil Department of Microbiology Faculty of Medicine Chiang Mai University 25 August 2015 ว ตถ ประสงค หล งจากช วโมงบรรยายน แล วน กศ กษาสามารถ
6/20/2014. PART I: Plasma Cell Myeloma. Plasma Cells
MULTIPLE MYELOMA: THE TESTING, VALIDATION AND IMPLEMENTATION OF CELL SEPARATION TECHNOLOGY FOR IMPROVED PATIENT CARE Elizabeth Harper CG(ASCP), Binh Vo CG(ASCP), Joey Pena CG(ASCP), Denise Lovshe CG(ASCP),
Immunophenotypic Analysis of Peripheral T-Cell Neoplasms A Multiparameter Flow Cytometric Approach
Hematopathology / FLOW CYTOMETRY OF T-CELL NEOPLASMS Immunophenotypic Analysis of Peripheral T-Cell Neoplasms A Multiparameter Flow Cytometric Approach Saba Jamal, MD, * Louis J. Picker, MD, * Deborah
UNDERSTANDING MULTIPLE MYELOMA AND LABORATORY VALUES Benjamin Parsons, DO bmparson@gundersenhealth.org Gundersen Health System Center for Cancer and
UNDERSTANDING MULTIPLE MYELOMA AND LABORATORY VALUES Benjamin Parsons, DO bmparson@gundersenhealth.org Gundersen Health System Center for Cancer and Blood Disorders La Crosse, WI UNDERSTANDING MULTIPLE
The use of monoclonal antibodies in the setting of HSCT
The use of monoclonal antibodies in the setting of HSCT S Montoto, Barts Cancer Institute, London, UK Geneva 3/April/2012 www.ebmt.org Some definitions of interest: Ab and Ag Antibody (Ab)=Immunoglobulin
Subclassifying DLBCL. Diffuse Large B-Cell Lymphoma: Variants & Subtypes. Subclassifying DLBCL
Diffuse Large B-Cell Lymphoma: Variants & Subtypes Patrick Treseler, MD, PhD University of California San Francisco Subclassifying DLBCL An Entity in Search of a Meaningful Classification Subclassifying
Emerging New Prognostic Scoring Systems in Myelodysplastic Syndromes 2012
Emerging New Prognostic Scoring Systems in Myelodysplastic Syndromes 2012 Arjan A. van de Loosdrecht, MD, PhD Department of Hematology VU University Medical Center VU-Institute of Cancer and Immunology
Multicolor Bead Flow Cytometry Standardization Heba Degheidy MD, PhD, QCYM DB/OSEL/CDRH/FDA Manager of MCM Flow Cytometry Facility
Multicolor Bead Flow Cytometry Standardization Heba Degheidy MD, PhD, QCYM DB/OSEL/CDRH/FDA Manager of MCM Flow Cytometry Facility The mention of commercial products, their sources, or their use in connection
Collaboration to collect Autologous transplant outcomes in Lymphoma and Myeloma (CALM) Additional Questionnaire (MED C) INCLUSION CRITERIA CALM STUDY
Additional Questionnaire (MED C) CALM study Inclusion period: 01/01/2008 to 31/12/2011 PATIENT REGISTRATION FORM Disease Diagnosis Lymphoma S Non Hodgkin Lymphoma (NHL) Mature B-cell neoplasm Follicular
Genomic Analysis of Mature B-cell Malignancies
Genomic Analysis of Mature B-cell Malignancies Update and Lessons Learned Omar Abdel-Wahab, MD Memorial Sloan Kettering Cancer Center Human Oncology and Pathogenesis Program and Leukemia Service Disclaimer:
What to know about the B-cell neoplasms Steven H. Swerdlow, M.D.
What to know about the B-cell neoplasms Steven H. Swerdlow, M.D. Bullet points and key words The 2008 Revised WHO monograph on Tumours of the haematopoietic and lymphoid tissues includes many changes among
Update on Diagnosis and Treatment of Lymphoma
Update on Diagnosis and Treatment of Lymphoma Wei Ai, M.D., Ph.D. Assistant Clinical Professor of Medicine May 2010 Cancer Incidence New Cancer Cases Lymphoma 63,000 - NHL 53,600 - HL 75,00 Cancer Death
CHAPTER 26 LATE BREAKING DEVELOPMENTS: IMPACT OF ANTI-CD20 MONOCLONAL ANTIBODIES ON LYMPHOMA THERAPY
CHAPTER 26 LATE BREAKING DEVELOPMENTS: IMPACT OF ANTI-CD20 MONOCLONAL ANTIBODIES ON LYMPHOMA THERAPY 26.1 Introduction rituximab Subsequent to the completion of drafts for the guidelines earlier in 2004,
Cytology of Lymph Nodes
Indications Cytology of Lymph Nodes Lymph node enlargement That was easy Mary Anna Thrall Don Meuten Indications Lymph node enlargement Suspect metastasis Normal sized lymph nodes are Normal Do NOT aspirate
Types, production of antibodies and Antibody/antigen interaction
Types, production of antibodies and Antibody/antigen interaction Antibodies Secreted by B lymphocytes Great diversity and specificity: >109 different antibodies; can distinguish between very similar molecules
Interesting Case Series. Periorbital Richter Syndrome
Interesting Case Series Periorbital Richter Syndrome MarkGorman,MRCS,MSc, a Julia Ruston, MRCS, b and Sarath Vennam, BMBS a a Division of Plastic Surgery, Royal Devon and Exeter Hospital, Exeter, Devon,
Aggressive lymphomas. Michael Crump Princess Margaret Hospital
Aggressive lymphomas Michael Crump Princess Margaret Hospital What are the aggressive lymphomas? Diffuse large B cell Mediastinal large B cell Anaplastic large cell Burkitt lymphoma (transformed lymphoma:
Chronic lymphocytic EBMT Slideleukemia. University of Heidelberg, Germany March 22, 2010. The European Group for Blood and Marrow Transplantation
Chronic lymphocytic EBMT Slideleukemia template Peter Barcelona Dreger Chairman, CLL 7 February subcommittee 2008 University of Heidelberg, Germany March 22, 2010 The European Group for Blood and Marrow
Allergy and Immunology Review Corner: Chapter 21 of Immunology IV: Clinical Applications in Health and Disease, by Joseph A. Bellanti, MD.
Allergy and Immunology Review Corner: Chapter 21 of Immunology IV: Clinical Applications in Health and Disease, by Joseph A. Bellanti, MD. Chapter 21: Transplantation Immunity and Clinical Applications
Oncology Best Practice Documentation
Oncology Best Practice Documentation Click on the desired Diagnoses link or press Enter to view all information. Diagnoses: Solid Tumors Lymphomas Leukemias Myelodysplastic Syndrome Pathology Findings
Overview. Transcriptional cascades. Amazing aspects of lineage plasticity. Conventional (B2) B cell development
Overview B cell development Transcriptional cascades Amazing aspects of lineage plasticity Conventional (B2) B cell development What happens to an autoreactive B cell? B1 vs B2 cells Key anatomical sites
Diffuse Large B-cell Lymphoma, Burkitt Lymphoma and the Gray Zone. Relative Frequency of B-cell NHL. Diffuse Large B-cell Lymphoma Definition
Diffuse Large B-cell Lymphoma, Burkitt Lymphoma and the Gray Zone L. Jeffrey Medeiros, M.D. M.D. Anderson Cancer Center Relative Frequency of B-cell NHL Diffuse large B-cell lymphoma 37 % Follicular lymphoma
Two Retroperitoneal Low-Grade B-Cell Lymphoma Successfully Treated With a Combination of Chimeric Anti-CD20 Monoclonal Antibody and CHOP Chemotherapy
Two Retroperitoneal Low-Grade B-Cell Lymphoma Successfully Treated With a Combination of Chimeric Anti-CD20 Monoclonal Antibody and CHOP Chemotherapy Yoichi Kitamura, MD Kazuhiko Hayashi, MD Kazumi Uchida,
WHOLE BLOOD LYSING SOLUTION FOR FLOW CYTOMETRIC APPLICATIONS
FOR IN-VITRO DIAGNOSTIC USE INVITROGEN CAL-LYSE TM Lysing Solution WHOLE BLOOD LYSING SOLUTION FOR FLOW CYTOMETRIC APPLICATIONS CAL-LYSE TM CATALOG No. GAS-010 250 tests 25 ml CATALOG No. GAS-010S-100
Clinical Information Systems to Support Personalized Medicine at the Bedside
Clinical Information Systems to Support Personalized Medicine at the Bedside March 2012 Mia Levy, MD, PhD Director Cancer Clinical Informatics, Vanderbilt Ingram Cancer Center Assistant Professor of Biomedical
Hodgkin and Non-Hodgkin Lymphoma Pre-HCT Data
(Form 2018) This section of the CIBMTR Forms Instruction Manual is intended to be a resource for completing the Hodgkin and Non-Hodgkin Lymphoma Pre-HCT Data Form. E-mail comments regarding the content
Anaplastic large cell lymphoma (ALCL) accounts for approximately
Original Articles Flow Cytometric Immunophenotyping of Anaplastic Large Cell Lymphoma Tariq Muzzafar, MD; Eric X. Wei, MD, PhD; Pei Lin, MD; L. Jeffrey Medeiros, MD; Jeffrey L. Jorgensen, MD, PhD Context.
Cancer. 9p21.3 deletion. t(12;21) t(15;17)
CANCER FISH PROBES INDIVIDUAL AND PANEL S Acute Lymphoblastic Leukemia (ALL) ALL FISH Panel (includes all probes below) 8010 LSI MYB/CEP6 LSI p16 (CDKN2A) LSI BCR/ABL with ASS LSI ETV6 (TEL)/AML1 (RUNX1)
Chapter 6. Antigen-Antibody Properties 10/3/2012. Antigen-Antibody Interactions: Principles and Applications. Precipitin reactions
Chapter 6 Antigen-Antibody Interactions: Principles and Applications Antigen-Antibody Properties You must remember antibody affinity (single) VS avidity (multiple) High affinity: bound tightly and longer!
Treating Minimal Residual Disease in Acute Leukemias: How low should you go?
Treating Minimal Residual Disease in Acute Leukemias: How low should you go? Ramsie Lujan, Pharm.D. PGY1 Pharmacy Practice Resident Methodist Hospital, San Antonio, Texas Pharmacotherapy Education and
Hairy Cell Leukemia Facts
No. 16 in a series providing the latest information for patients, caregivers and healthcare professionals www.lls.org Information Specialist: 800.955.4572 Highlights l Hairy cell leukemia (HCL) is a chronic
FDA approves Rituxan/MabThera for first-line maintenance use in follicular lymphoma
Media Release Basel, 31 January 2011 FDA approves Rituxan/MabThera for first-line maintenance use in follicular lymphoma Approval provides option that improves the length of time people with incurable
Stem Cell Transplantation
Harmony Behavioral Health, Inc. Harmony Behavioral Health of Florida, Inc. Harmony Health Plan of Illinois, Inc. HealthEase of Florida, Inc. Ohana Health Plan, a plan offered by WellCare Health Insurance
Challenging Diagnosis in Hematopathology
Challenging Diagnosis in Hematopathology S. David Hudnall, M.D. Professor of Pathology & Laboratory Medicine Chief, Division of Hematopathology Yale University School of Medicine dhudnall@yale.edu Challenging
PROGNOSIS IN ACUTE LYMPHOBLASTIC LEUKEMIA PROGNOSIS IN ACUTE MYELOID LEUKEMIA
PROGNOSIS IN ACUTE LYMPHOBLASTIC LEUKEMIA UNFAVORABLE Advanced age High leukocyte count at diagnosis Presence of myeloid antigens Late achievement of CR Chromosomal abnormalities: t(9:22)(q34:q11) t(4;11)(q21;q23)
亞 東 紀 念 醫 院 Follicular Lymphoma 臨 床 指 引
前 言 : 惡 性 淋 巴 瘤 ( 或 簡 稱 淋 巴 癌 ) 乃 由 體 內 淋 巴 系 統 包 括 淋 巴 細 胞 淋 巴 管 淋 巴 腺 及 一 些 淋 巴 器 官 或 組 織 如 脾 臟 胸 腺 及 扁 桃 腺 等 所 長 出 的 惡 性 腫 瘤 依 腫 瘤 病 理 組 織 型 態 的 不 同 可 分 為 何 杰 金 氏 淋 巴 瘤 (Hodgkin s disease) 與 非 何 杰 金
What Leukemia Is. Understanding blood
Leukemia is a malignant disease of the blood-forming cells. It involves white blood cells that do not mature and that reproduce too rapidly. Eventually, they replace the normal bone marrow, leaving insufficient
FastTest. You ve read the book... ... now test yourself
FastTest You ve read the book...... now test yourself To ensure you have learned the key points that will improve your patient care, read the authors questions below. Please refer back to relevant sections
Study of serum protein electrophoresis in suspected cases of Multiple Myeloma.
Journal homepage: http://www.journalijar.com INTERNATIONAL JOURNAL OF ADVANCED RESEARCH RESEARCH ARTICLE Study of serum protein electrophoresis in suspected cases of Multiple Myeloma. Dr. Dharmishtha N.
Lymphoid Neoplasms. Sylvie Freeman Department of Clinical Immunology, University of Birmingham
Lymphoid Neoplasms Sylvie Freeman Department of Clinical Immunology, University of Birmingham Incidence of Haematological Malignancies UK2001 (CRUK) Malignancy New Cases All Cancers 271,000 Leukaemia 6,760
Canine lymphoproliferative disorders often present
J Vet Intern Med 2008;22:596 601 Canine Lymphoproliferative Disease Characterized by Lymphocytosis: Immunophenotypic Markers of Prognosis M.J. Williams, A.C. Avery, S.E. Lana, K.R. Hillers, A.M. Bachand,